These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 18333783)
1. Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics. Lysaght MJ; Jaklenec A; Deweerd E Tissue Eng Part A; 2008 Feb; 14(2):305-15. PubMed ID: 18333783 [TBL] [Abstract][Full Text] [Related]
2. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry. Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399 [TBL] [Abstract][Full Text] [Related]
3. The need for a regen industry voice. Mason C; Dunnill P Regen Med; 2008 Sep; 3(5):621-31. PubMed ID: 18729785 [No Abstract] [Full Text] [Related]
4. Regenerative medicine: a primer for paediatricians. Polak DJ Early Hum Dev; 2009 Nov; 85(11):685-9. PubMed ID: 19783108 [TBL] [Abstract][Full Text] [Related]
5. Genetically modified cells in regenerative medicine and tissue engineering. Sheyn D; Mizrahi O; Benjamin S; Gazit Z; Pelled G; Gazit D Adv Drug Deliv Rev; 2010 Jun; 62(7-8):683-98. PubMed ID: 20114067 [TBL] [Abstract][Full Text] [Related]
7. Engineering organs. Atala A Curr Opin Biotechnol; 2009 Oct; 20(5):575-92. PubMed ID: 19896823 [TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stem cells for tissue engineering and regenerative medicine. Tae SK; Lee SH; Park JS; Im GI Biomed Mater; 2006 Jun; 1(2):63-71. PubMed ID: 18460758 [TBL] [Abstract][Full Text] [Related]
9. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States. Lee MH; Arcidiacono JA; Bilek AM; Wille JJ; Hamill CA; Wonnacott KM; Wells MA; Oh SS Tissue Eng Part B Rev; 2010 Feb; 16(1):41-54. PubMed ID: 19728784 [TBL] [Abstract][Full Text] [Related]
10. Scaffold-free cell delivery for use in regenerative medicine. Kelm JM; Fussenegger M Adv Drug Deliv Rev; 2010 Jun; 62(7-8):753-64. PubMed ID: 20153387 [TBL] [Abstract][Full Text] [Related]
11. Hurdles in tissue engineering/regenerative medicine product commercialization: a survey of North American academia and industry. Johnson PC; Bertram TA; Tawil B; Hellman KB Tissue Eng Part A; 2011 Jan; 17(1-2):5-15. PubMed ID: 20726816 [TBL] [Abstract][Full Text] [Related]
13. Delivery of biologics in cardiovascular regenerative medicine. Bartunek J; Sherman W; Vanderheyden M; Fernandez-Aviles F; Wijns W; Terzic A Clin Pharmacol Ther; 2009 May; 85(5):548-52. PubMed ID: 19212313 [No Abstract] [Full Text] [Related]
14. [The industrialization of regenerative medicine--a potential market of $ 500 billion]. Gu Q; Zhang X; Jiang L Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Sep; 21(9):1011-5. PubMed ID: 17933243 [TBL] [Abstract][Full Text] [Related]
15. Stem cell and regenerative science applications in the development of bioengineering of renal tissue. Perin L; Giuliani S; Sedrakyan S; DA Sacco S; De Filippo RE Pediatr Res; 2008 May; 63(5):467-71. PubMed ID: 18427289 [TBL] [Abstract][Full Text] [Related]